Adele M. Gulfo
Known title: DirectorCIK: 0001647102
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
RBC Capital Lowers Target to $42 for NAMS. RBC Capital has kept its outperform rating for NewAmsterdam Pharma (NAMS) but cut its price target to $42. The new target sits at the top of the 52‑week range and near the current support level of $35.04. The stock’s RSI of 33.5 suggests it is in an oversold zone, which may influence short‑term trading activity. Analysts still see upside potential, but the lowered target reflects a more cautious outlook.
Transaction History
| NPO | ▲ Buy | Grant | 567 | $140K | 2/12/2026 | View on chart |
| NAMS | ▲ Buy | Grant | 3,400 | — | 1/7/2026 | View on chart |
| NAMS | ▲ Buy | Grant | 10,860 | — | 4/15/2025 | View on chart |
| NPO | ▲ Buy | Grant | 803 | $125K | 2/15/2024 | View on chart |
| NPO | ▲ Buy | Grant | 942 | $110K | 2/16/2023 | View on chart |
| NPO | ▲ Buy | Grant | 1,041 | $110K | 2/15/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
NPO highlighted in recent stock comparison articles
Recent articles from ChartMill and Yahoo Finance have featured Enpro Inc. (NPO) in discussions about cash-producing stocks and value comparisons. These pieces analyze the company's financial metrics, such as return on invested capital and cash conversion, alongside its peer YMM. The coverage positions NPO as a subject of interest for investors evaluating quality and growth factors in the current market.
NPO highlighted in recent stock comparison articles. Recent articles from ChartMill and Yahoo Finance have featured Enpro Inc. (NPO) in discussions about cash-producing stocks and value comparisons. These pieces analyze the company's financial metrics, such as return on invested capital and cash conversion, alongside its peer YMM. The coverage positions NPO as a subject of interest for investors evaluating quality and growth factors in the current market.